Innocan Pharma - CEO Iris Bincovish
CEO Iris Bincovish
Source: Innocan Pharma
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Innocan Pharma’s (INNO) patent application that claims cannabinoid-based topical compositions can treat psoriasis of the scalp has reached the national phase
  • The global psoriasis therapeutics market size was valued at USD $22.9 billion in 2021 and is projected to reach USD $55.8 billion by 2031
  • The national phase is a major milestone in a patent lifecycle, allowing the company to protect its pharmaceutical products in the major business countries in the world
  • Innocan Pharma (INNO) is up 1.67 per cent, trading at C$0.30 as of 10:15 am ET

Innocan Pharma’s (INNO) patent application, which claims cannabinoid-based topical compositions can treat psoriasis of the scalp, has reached the national phase.

Innocan’s PCT application WO2021/240505 for the composition presents the potential for treatment without providing an unaesthetic appearance and without causing irritation to the scalp.

Psoriasis of the scalp is a skin disorder associated with dry scalp, scaly patches on the scalp, hair loss, burning, soreness and white scales. According to an Allied Market Research report from September 2022, the global psoriasis therapeutics market size was valued at USD $22.9 billion in 2021 and is projected to reach USD $55.8 billion by 2031.

The national phase is a major milestone in a patent lifecycle, allowing the company to protect its pharmaceutical products in major business countries in the world.

Innocan Pharma (INNO) is a pharmaceutical tech company that operates under two main segments: pharmaceuticals and consumer wellness.

Innocan Pharma (INNO) is up 1.67 per cent, trading at C$0.30 as of 10:15 am ET.


More From The Market Herald

" Voyageur (TSXV:VM) completes SmoothX testing

Voyageur Pharmaceuticals (VM) has completed the production test batch of its SmoothX product for the computerized tomography (CT) imaging market in Canada.
Aleafia Health - CEO, Tricia Symmes

" Aleafia Health (TSX:AH) completes TSX review and enters fifth province

Aleafia Health (AH) has completed the TSX delisting review and has satisfied the Toronto Stock Exchange’s requirements for continued listing.

" Alpha Cognition (TSXV:ACOG) withdraws public offering

Alpha Cognition (ACOG) has withdrawn its previously-announced marketed public offering.
Bright Mind Biosciences - CEO, Ian McDonald

" Bright Minds Biosciences (CSE:DRUG) announces non-brokered private placement

Bright Minds Biosciences (DRUG) has announced a non-brokered private placement of gross proceeds of $2,050,000.